Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

2.

Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods.

Grahn A, Bråve A, Tolfvenstam T, Studahl M.

Emerg Infect Dis. 2018 Jun;24(6):978-987. doi: 10.3201/eid2406.172097.

3.

Network Experiences from a Cross-Sector Biosafety Level-3 Laboratory Collaboration: A Swedish Forum for Biopreparedness Diagnostics.

Thelaus J, Lindberg A, Thisted Lambertz S, Byström M, Forsman M, Lindmark H, Knutsson R, Båverud V, Bråve A, Jureen P, Lundin Zumpe A, Melefors Ö.

Health Secur. 2017 Jul/Aug;15(4):384-391. doi: 10.1089/hs.2016.0082. Epub 2017 Aug 14.

4.

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Hinkula J, Petkov S, Ljungberg K, Hallengärd D, Bråve A, Isaguliants M, Falkeborn T, Sharma S, Liakina V, Robb M, Eller M, Moss B, Biberfeld G, Sandström E, Nilsson C, Markland K, Blomberg P, Wahren B.

Heliyon. 2017 Jun 29;3(6):e00339. doi: 10.1016/j.heliyon.2017.e00339. eCollection 2017 Jun.

5.

Prioritization of High Consequence Viruses to Improve European Laboratory Preparedness for Cross-Border Health Threats.

Nisii C, Grunow R, Brave A, Ippolito G, Jacob D, Jureen P, Bartolini B, Di Caro A; EMERGE Viral Pathogens Working Group.

Adv Exp Med Biol. 2017;972:123-129. doi: 10.1007/5584_2016_152.

PMID:
28032326
6.

Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit.

Grahn A, Bråve A, Lagging M, Dotevall L, Ekqvist D, Hammarström H, Karlberg H, Lagerqvist N, Sansone M, Tegnell A, Ulleryd P, Studahl M.

Open Forum Infect Dis. 2016 Sep 20;3(4):ofw198. eCollection 2016 Oct.

7.

The contribution of the European high containment laboratories during the 2014-2015 Ebola Virus Disease emergency.

Nisii C, Vincenti D, Fusco FM, Schmidt-Chanasit J, Carbonnelle C, Raoul H, Eickmann M, Hewson R, Brave A, Nuncio S, Sanchez-Seco MP, Palyi B, Kis Z, Zange S, Nitsche A, Kurth A, Strasser M, Capobianchi MR, Ozin A, Guglielmetti P, Menel-Lemos C, Jacob D, Grunow R, Ippolito G, Di Caro A.

Clin Microbiol Infect. 2017 Feb;23(2):58-60. doi: 10.1016/j.cmi.2016.07.003. Epub 2016 Jul 9. No abstract available.

8.

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.

Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, Biberfeld G, Sandström E, Wahren B.

PLoS One. 2015 Jun 29;10(6):e0131748. doi: 10.1371/journal.pone.0131748. eCollection 2015.

9.

Draft Genome Sequence of Strain R13-38 from a Francisella tularensis Outbreak in Sweden.

Alm E, Advani A, Bråve A, Wahab T.

Genome Announc. 2015 Feb 19;3(1). pii: e01517-14. doi: 10.1128/genomeA.01517-14.

10.

Oral delivery of plant-derived HIV-1 p24 antigen in low doses shows a superior priming effect in mice compared to high doses.

Lindh I, Bråve A, Hallengärd D, Hadad R, Kalbina I, Strid Å, Andersson S.

Vaccine. 2014 Apr 25;32(20):2288-93. doi: 10.1016/j.vaccine.2014.02.073. Epub 2014 Mar 12.

PMID:
24631072
11.

Immunotherapy with an HIV-DNA Vaccine in Children and Adults.

Palma P, Gudmundsdotter L, Finocchi A, Eriksson LE, Mora N, Santilli V, Aquilani A, Manno EC, Zangari P, Romiti ML, Montesano C, Grifoni A, Brave A, Ljungberg K, Blomberg P, Bernardi S, Sandström E, Hejdeman B, Rossi P, Wahren B.

Vaccines (Basel). 2014 Jul 17;2(3):563-80. doi: 10.3390/vaccines2030563.

12.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

13.

Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Falkeborn T, Bråve A, Larsson M, Akerlind B, Schröder U, Hinkula J.

PLoS One. 2013 Aug 8;8(8):e70527. doi: 10.1371/journal.pone.0070527. eCollection 2013.

14.

A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity.

Hallengärd D, Wahren B, Bråve A.

Viral Immunol. 2013 Apr;26(2):163-6. doi: 10.1089/vim.2012.0083.

PMID:
23573980
15.

Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009.

Mörner A, Bråve A, Kling AM, Kühlmann-Berenzon S, Krook K, Hedenskog M, Silhammar I, Ljungman M, Ortqvist A, Andersson S, Brytting M, Thorstensson R, Linde A.

PLoS One. 2012;7(12):e53511. doi: 10.1371/journal.pone.0053511. Epub 2012 Dec 28.

16.

DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.

Nyström S, Bråve A, Falkeborn T, Devito C, Rissiek B, Johansson DX, Schröder U, Uematsu S, Akira S, Hinkula J, Applequist SE.

Vaccines (Basel). 2013 Sep 25;1(4):415-43. doi: 10.3390/vaccines1040415.

17.

Cellular immunogenicity of novel gene immunogens in mice monitored by in vivo imaging.

Starodubova E, Krotova O, Hallengärd D, Kuzmenko Y, Engström G, Legzdina D, Latyshev O, Eliseeva O, Karin Maltais A, Tunitskaya V, Karpov V, Bråve A, Isaguliants M.

Mol Imaging. 2012 Nov-Dec;11(6):471-86.

PMID:
23084248
18.

Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses.

Hallengärd D, Applequist SE, Nyström S, Maltais AK, Marovich M, Moss B, Earl P, Nihlmark K, Wahren B, Bråve A.

Viral Immunol. 2012 Oct;25(5):423-32. doi: 10.1089/vim.2012.0046.

PMID:
23035853
19.

A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines.

Hallengärd D, Bråve A, Isaguliants M, Blomberg P, Enger J, Stout R, King A, Wahren B.

Genet Vaccines Ther. 2012 Aug 8;10(1):5. doi: 10.1186/1479-0556-10-5.

20.

Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity.

Boberg A, Stålnacke A, Bråve A, Hinkula J, Wahren B, Carlin N.

ISRN Mol Biol. 2012 Jul 15;2012:170676. doi: 10.5402/2012/170676. eCollection 2012.

21.

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, Aris EA, Lyamuya EF, Janabi M, Godoy-Ramirez K, Joachim A, Polonis VR, Bråve A, Earl P, Robb M, Marovich M, Wahren B, Pallangyo K, Biberfeld G, Mhalu F, Sandström E.

Vaccine. 2011 Oct 26;29(46):8417-28. doi: 10.1016/j.vaccine.2011.08.001. Epub 2011 Aug 22.

22.

Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation.

Hallengärd D, Haller BK, Maltais AK, Gelius E, Nihlmark K, Wahren B, Bråve A.

Clin Vaccine Immunol. 2011 Sep;18(9):1577-81. doi: 10.1128/CVI.05045-11. Epub 2011 Jul 13.

23.

The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.

Palma P, Romiti ML, Li Pira G, Montesano C, Mora N, Aquilani A, Santilli V, Tchidjou HK, Ivaldi F, Giovannelli L, Pontrelli G, Borra G, Blomberg P, Gudmundsdotter L, Bråve A, Montano M, Bernardi S, Manca F, Wahren B, Rossi P.

Vaccine. 2011 Sep 9;29(39):6810-6. doi: 10.1016/j.vaccine.2010.12.058. Epub 2011 Jan 7.

PMID:
21216310
24.

Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity.

Hallengärd D, Haller BK, Petersson S, Boberg A, Maltais AK, Isaguliants M, Wahren B, Bråve A.

Vaccine. 2011 Jan 17;29(4):839-48. doi: 10.1016/j.vaccine.2010.10.083. Epub 2010 Nov 23.

PMID:
21109032
25.

Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation.

Bråve A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, Hejdeman B, Biberfeld G, Wahren B.

Vaccine. 2010 Nov 29;28(51):8203-9. doi: 10.1016/j.vaccine.2010.08.108. Epub 2010 Oct 15.

PMID:
20951666
26.

Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses.

Bråve A, Nyström S, Roos AK, Applequist SE.

Immunol Cell Biol. 2011 Mar;89(3):492-6. doi: 10.1038/icb.2010.109. Epub 2010 Sep 14.

PMID:
20838412
27.

Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like ligand 4 in mammary carcinoma.

Haller BK, Bråve A, Wallgard E, Roswall P, Sunkari VG, Mattson U, Hallengärd D, Catrina SB, Hellström M, Pietras K.

Oncogene. 2010 Jul 29;29(30):4276-86. doi: 10.1038/onc.2010.176. Epub 2010 May 24.

PMID:
20498640
28.

Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L.

Lancet Infect Dis. 2010 May;10(5):305-16. doi: 10.1016/S1473-3099(10)70069-4.

PMID:
20417413
29.

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes.

Brave A, Johansson U, Hallengärd D, Heidari S, Gullberg H, Wahren B, Hinkula J, Spetz AL.

Vaccine. 2010 Feb 25;28(9):2080-7. doi: 10.1016/j.vaccine.2009.12.040. Epub 2009 Dec 29.

PMID:
20044053
30.

Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment.

Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P.

PLoS One. 2009 Sep 30;4(9):e7226. doi: 10.1371/journal.pone.0007226.

31.

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.

Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B.

Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29.

32.

Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.

Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, Hallermalm K.

Vaccine. 2009 Jun 8;27(28):3692-6. doi: 10.1016/j.vaccine.2009.04.013. Epub 2009 May 3.

PMID:
19428161
33.

Feeding of mice with Arabidopsis thaliana expressing the HIV-1 subtype C p24 antigen gives rise to systemic immune responses.

Lindh I, Kalbina I, Thulin S, Scherbak N, Sävenstrand H, Bråve A, Hinkula J, Strid A, Andersson S.

APMIS. 2008 Nov;116(11):985-94. doi: 10.1111/j.1600-0463.2008.00900.x.

PMID:
19132995
34.

Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses.

Bråve A, Hallengärd D, Malm M, Blazevic V, Rollman E, Stanescu I, Krohn K.

Vaccine. 2009 Jan 7;27(2):184-6. doi: 10.1016/j.vaccine.2008.10.041. Epub 2008 Nov 4.

PMID:
18992294
35.

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Sandström E, Nilsson C, Hejdeman B, Bråve A, Bratt G, Robb M, Cox J, Vancott T, Marovich M, Stout R, Aboud S, Bakari M, Pallangyo K, Ljungberg K, Moss B, Earl P, Michael N, Birx D, Mhalu F, Wahren B, Biberfeld G; HIV Immunogenicity Study 01/02 Team.

J Infect Dis. 2008 Nov 15;198(10):1482-90. doi: 10.1086/592507.

36.

Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.

Bråve A, Johansen K, Palma P, Benthin R, Hinkula J.

Vaccine. 2008 Nov 5;26(47):5957-66. doi: 10.1016/j.vaccine.2008.08.060. Epub 2008 Sep 16.

PMID:
18801400
37.

Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin.

Boberg A, Gaunitz S, Bråve A, Wahren B, Carlin N.

Vaccine. 2008 Sep 19;26(40):5079-82. doi: 10.1016/j.vaccine.2008.03.096. Epub 2008 Apr 24.

PMID:
18514370
38.

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.

Bråve A, Hallengärd D, Schröder U, Blomberg P, Wahren B, Hinkula J.

Vaccine. 2008 Sep 19;26(40):5075-8. doi: 10.1016/j.vaccine.2008.03.066. Epub 2008 Apr 15.

PMID:
18450334
39.

Murine models for HIV vaccination and challenge.

Boberg A, Bråve A, Johansson S, Wahren B, Hinkula J, Rollman E.

Expert Rev Vaccines. 2008 Feb;7(1):117-30. doi: 10.1586/14760584.7.1.117. Review.

PMID:
18251698
40.

Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.

Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E.

Vaccine. 2007 Sep 28;25(39-40):6882-90. Epub 2007 Jul 27.

PMID:
17707956
41.

Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology.

Bråve A, Gudmundsdotter L, Gasteiger G, Hallermalm K, Kastenmuller W, Rollman E, Boberg A, Engström G, Reiland S, Cosma A, Drexler I, Hinkula J, Wahren B, Erfle V.

Infect Agent Cancer. 2007 Jul 10;2:14.

42.

Pre-clinical evaluation of a CEA DNA prime/protein boost vaccination strategy against colorectal cancer.

Hallermalm K, Johansson S, Bråve A, Ek M, Engström G, Boberg A, Gudmundsdotter L, Blomberg P, Mellstedt H, Stout R, Liu MA, Wahren B.

Scand J Immunol. 2007 Jul;66(1):43-51. doi: 10.1111/j.1365-3083.2007.01945.x.

43.

A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.

Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B.

Mol Ther. 2007 Sep;15(9):1724-33. Epub 2007 Jun 19.

44.

Immunization with HIV protease peptides linked to syngeneic erythrocytes.

Boberg A, Dominici S, Brave A, Hallermalm K, Hinkula J, Magnani M, Wahren B.

Infect Agent Cancer. 2007 Apr 18;2:9.

45.

Vaccine delivery methods using viral vectors.

Bråve A, Ljungberg K, Wahren B, Liu MA.

Mol Pharm. 2007 Jan-Feb;4(1):18-32. Review.

PMID:
17274663
46.

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.

Rollman E, Mathy N, Bråve A, Boberg A, Kjerrström A, van Wely C, Engström G, Johansson S, Aperia K, Eriksson LE, Benthin R, Ertl P, Heeney J, Hinkula J, Voss G, Wahren B.

Vaccine. 2007 Mar 1;25(11):2145-54. Epub 2006 Nov 13.

PMID:
17254672
47.

The rationale behind a vaccine based on multiple HIV antigens.

Rollman E, Bråve A, Boberg A, Gudmundsdotter L, Engström G, Isaguliants M, Ljungberg K, Lundgren B, Blomberg P, Hinkula J, Hejdeman B, Sandström E, Liu M, Wahren B.

Microbes Infect. 2005 Nov;7(14):1414-23. Epub 2005 Sep 29.

PMID:
16257558
48.

Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine.

Bråve A, Ljungberg K, Boberg A, Rollman E, Engström G, Hinkula J, Wahren B.

Vaccine. 2006 May 22;24(21):4524-6. Epub 2005 Aug 18.

PMID:
16174543
49.

Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.

Bråve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B.

Mol Ther. 2005 Dec;12(6):1197-205. Epub 2005 Aug 22.

50.

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

Zuber AK, Bråve A, Engström G, Zuber B, Ljungberg K, Fredriksson M, Benthin R, Isaguliants MG, Sandström E, Hinkula J, Wahren B.

Vaccine. 2004 Apr 16;22(13-14):1791-8.

PMID:
15068863

Supplemental Content

Support Center